These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30339245)

  • 1. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
    Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
    Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
    Lien HC; Lo C; Lee YH; Lin PH; Wang MY; Kuo WH; Tsai LW; Lu YS; Hu HW; Li YC; Huang CS
    Breast Cancer Res; 2024 Jun; 26(1):100. PubMed ID: 38867307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study.
    Memon R; Prieto Granada CN; Harada S; Winokur T; Reddy V; Kahn AG; Siegal GP; Wei S
    Clin Breast Cancer; 2022 Jan; 22(1):e123-e133. PubMed ID: 34120846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
    Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
    Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
    Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
    Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
    Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Wang Y; Singh K; Dizon D; Graves T; Amin A; Yakirevich E
    Breast Cancer Res Treat; 2021 Apr; 186(3):667-676. PubMed ID: 33598878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study.
    Jiao D; Li G; Dai H; Wang J; Zhang J; Hou Y; Guo X; Zhao Y; Gong X; Liu Z
    Oncologist; 2024 Jul; 29(7):e877-e886. PubMed ID: 38537665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer.
    Tseng YF; Li YC; Lee YH; Hu HW; Zhang MS; Hung TC; Lien HC
    Arch Pathol Lab Med; 2024 Mar; 148(3):e48-e56. PubMed ID: 37639453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
    Casterá C; Bernet L
    Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.